SEHK:2696Biotechs
Shanghai Henlius Biotech (SEHK:2696) Valuation in Focus After Landmark FDA Approval for POHERDY Biosimilar
Shanghai Henlius Biotech (SEHK:2696) is in focus after the US FDA approved its Biologics License Application for POHERDY. This approval makes POHERDY the first pertuzumab biosimilar available in the US through a partnership with Organon.
See our latest analysis for Shanghai Henlius Biotech.
Henlius’s recent FDA approval comes on the heels of a remarkable run. After some profit-taking, the stock’s latest price is HK$65.25, and its year-to-date share price return is an eye-catching 177.66%...